Using ctDNA to Inform Treatment in MIBC

This content was funded by Natera.

Discover how personalized ctDNA testing is transforming care for patients with muscle-invasive bladder cancer (MIBC). This interactive, expert-led webinar explores the latest evidence and practical applications of molecular residual disease (MRD) assessment across the treatment continuum.

What you’ll learn:

• How ctDNA serves as a dynamic biomarker to detect MRD and predict recurrence earlier than standard tools
• Clinical applications of Signatera™ for neoadjuvant response monitoring, postsurgical risk stratification, and surveillance
• Evidence from pivotal trials (IMvigor011, CheckMate 274, NIAGARA) demonstrating prognostic and predictive value of ctDNA
• How MRD-guided strategies enable precision treatment selection and improve disease-free and overall survival outcomes

Chapters

1. Introduction – 00:00 – 02:13
2. ctDNA Basics – 02:13 – 05:27
3. Signatera^TM Overview – 05:27 – 07:41
4. Signatera^TM in MIBC – 07:41 – 09:53
5. Perioperative Trials in MIBC – 09:53 – 13:40
6. Adjuvant Trials in MIBC: IMvigor010 & IMvigor011 – 13:40 – 22:39
7. Additional Adjuvant Trials in MIBC – 22:39 – 27:28
8. Takeaways & Discussion –  27:28 – 34:07

1. Fred Hutchinson Cancer Research Center, Seattle, Washington, USA